Page 91 - Sohini Das

Govt in talks with Moderna for vaccine, yet to receive cold chain plan

Moderna's vaccine can be stored at normal fridge temperatures of 2 to 8 degrees Celsius for 30 days and it can be stored up to six months at minus 20 degree Celsius, according to reports

Pfizer may price Covid-19 vaccine lower in India than in UK and US

Cold chain of agriculture research body may come in handy

Serum likely to submit final Covid-19 vaccine trial data in 10 days

If the data is found satisfactory, an approval for Covishield, Oxford-AstraZeneca's vaccine candidate, can come in by the first week of January

Centre may not procure Pfizer-BioNTech Covid vaccine over high cost

At $37 per dose, the Pfizer vaccine is much more expensive compared to $3 per dose for the Covishield

Shelf life of vaccines likely to be more than 3 months, unlike drugs

They have the stability data for these investigational products, said a source

Recruited 8,000 volunteers already for phase 3 trials: Bharat Biotech head

The company says they are '200% transparent' about serious adverse events with regulator

ZyCoV-D shot can remain stable at room temperature: Zydus Cadila chairman

The company plans to apply for approval once it finishes phase 3 trials

Cipla settles blood cancer drug litigation with Bristol Myers in US

As it takes away the legal overhang, Cipla can launch the drug once its ANDA is approved

Gennova mRNA vaccine stable above sub-zero temperatures unlike global peers

The messenger RNA vaccine candidate contains a short, synthetic version encoding the spike protein (antigen) of the novel coronavirus Sars-CoV-2

Pune's Gennova gets nod for clinical trials of India's first mRNA vaccine

DCGI granted conditional approval for phase 1 and 2 clinical trials of Gennova's mRNA based Covid-19 vaccine candidate

Review panel asks vaccine makers to submit more data to get authorisation

Experts ask Bharat Biotech for phase 3 data, Serum's UK approval status

Expert panel set to review Pfizer-BioNTech, SII vaccine applications today

ICMR Director General Balram Bhargava said that in the case of temporary licensure or emergency use, the regulator had to be satisfied with the risk-benefit ratio.

Bharat Biotech applies for emergency use authorisation for Covaxin

The company is conducting a 26,000 subjects phase 3 efficacy trial in India to determine the efficacy of its candidate

Serum set for deal with Centre soon; to supply vaccine at Rs 250 a dose

There is still time before SII can start supplying to the low and medium income countries through Gavi

Decoded: What emergency use authorisation of Covid vaccine means for us

After the Indian arm of US pharmaceutical giant Pfizer, the Serum Institute of India has applied to the Drugs Controller General of India (DCGI) seeking emergency use authorisation

Pfizer working on cold storage issues to ensure temperature integrity

The company has developed detailed logistical plans and tools to support effective vaccine transport, storage, and temperature monitoring.

November domestic pharma sales grow just 1% after strong show last month

Oct growth rate was 9.6%; Most big corporates saw volumes drop in November

Vaccine efficacy based on 2 doses: Bharat Biotech after Vij tests positive

Covaxin is an indigenously developed Covid-19 vaccine undergoing a trial on over 26,000 people across 25 sites in India to evaluate the efficacy of the vaccine candidate

DCGI reassures all protocols being followed in Serum's clinical trials

The ethics committee has seven members, including a chairperson who has to be from outside the institution where the trial is being conducted.

Private health care providers gear up for Covid-19 vaccination drive

The industry, on its part, is drafting out the road map for vaccination and where they can chip in.